New mRNA vaccine could shield transplant patients from dangerous virus

NCT ID NCT05683457

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: ModernaTX, Inc. Source: ClinicalTrials.gov ↗

First seen Apr 04, 2026 · Last updated Apr 29, 2026 · Updated 4 times

Summary

This study tests an mRNA vaccine (mRNA-1647) to prevent cytomegalovirus (CMV) infection in people who have had a stem cell transplant. About 224 participants will receive either the vaccine or a placebo. The goal is to see if the vaccine can safely prevent serious CMV infections after patients stop taking preventive antiviral drugs.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS INFECTION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.

CYTOMEGALOVIRUS INFECTION